1 INTRODUCTION Intranasal esketamine has recently been approved as a novel treatment option for Major Depressive Disorder (MDD) and its use is increasing worldwide.1-3 Esketamine is a non-selective, non-competitive antagonist of the glutamatergic N-methyl-D Aspartate (NMDA) receptor and has robust antidepressant and anti-suicidal effects.4 In the Netherlands, intranasal esketamine is only reimbursed for patients with Treatment Resistant Depression (TRD) and requires administration in the...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Wietske L.
Contact Wietske L., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack